Comparison of gentamicin and tobramycin nephrotoxicity in patients receiving individualized-pharmacokinetic dosing regimens
Authors:
- 1 January 1982
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 3 (1) , 83-88
Abstract
The incidence of nephrotoxicity has been studied in 175 patients who received either gentamicin or tobramycin. All patients received individualized dosing regimens of the drugs based on pharmacokinetic parameters measured after the initial dose. Subsequent doses were calculated from the pharmacokinetic data to produce peak aminoglycoside levels of between 6 and 8 μg ml−1 and trough levels that were below 2 μg ml−1. Renal toxicity was defined as a 30 per cent or greater increase in the serum creatinine level above the baseline value. Five of the 125 patients (4 per cent) who received gentamicin, and 1 of the 39 patients (2.6 per cent) who received tobramycin developed signs of nephrotoxicity. This difference was not statistically significant.Keywords
This publication has 7 references indexed in Scilit:
- Double-Blind Comparison of the Nephrotoxicity and Auditory Toxicity of Gentamicin and TobramycinNew England Journal of Medicine, 1980
- Renal clearance and tissue accumulation of gentamicinClinical Pharmacology & Therapeutics, 1977
- Tobramycin Sulfate: A Summary of Worldwide Experience from Clinical TrialsThe Journal of Infectious Diseases, 1976
- Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patientsJournal of Pharmacokinetics and Biopharmaceutics, 1976
- Gentamicin Blood Levels: a Guide to NephrotoxicityAntimicrobial Agents and Chemotherapy, 1975
- Pharmacokinetics of Gentamicin: Distribution and Plasma and Renal ClearanceThe Journal of Infectious Diseases, 1971
- Renal Insufficiency Associated with Gentamicin TherapyThe Journal of Infectious Diseases, 1971